AACR Great Reading Was on AACR's website, I think Amorfix falls in this category, under program menu, cutting-edge trials selected for oral presentation. This got my attention as I asked my-self how does Amorfix get selected to present, you must have to give them something ? " Abstracts submitted for both the regular or the late-breaking deadlines will be considered by the program committee. Placeholder abstracts may be submitted by the January 28 late-breaking abstract deadline for clinical trials that only have preliminary data at the time of submission with final results to be submitted by March 1, 2013" Lots more but obviously the company is sharing data with different folks. As for the patent comment on the blog, don't buy it they had a patent on their PrP cancer antibody long ago, was even on Cedarlane a couple of years ago when they were offering PrP cancer antibodies to Pharma's and Academics for rearch.